2024-11-08 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis:

**1. Performance Overview**

Johnson & Johnson (JNJ) is a multinational pharmaceutical, medical device, and consumer packaged goods company. As of the latest data, JNJ's cumulative return is 31.61%, significantly underperforming the S&P 500 (VOO) with a cumulative return of 139.88%. This results in a substantial negative divergence of -108.27, representing the lowest point in its historical range.

**Alpha and Beta Analysis:**

The provided data shows a mixed picture for JNJ's alpha and beta values. While its beta generally hovers around 0.7, indicating lower volatility compared to the market, its alpha has been consistently negative over the past several years, suggesting it underperformed the market in most periods.

**2. Recent Price Movements**

As of the latest data, JNJ's closing price is 157.88. 

* **5-day moving average:** 158.89
* **20-day moving average:** 161.75
* **60-day moving average:** 162.64

This suggests that JNJ's price is currently below its short-term and long-term moving averages, indicating a possible downward trend. However, the last market price of 156.96 might suggest a recent dip, possibly stemming from a short-term event.

**3. Technical Indicators**

* **RSI:** 30.83. This indicates that JNJ is currently in oversold territory, suggesting potential for a rebound.
* **PPO:** -0.33.  A negative PPO indicates a bearish trend.
* **Delta_Previous_Relative_Divergence:** -4.19. This suggests a short-term downward trend in relative performance.
* **Expected Return:** 0.0%.  The expected return is estimated to be 0% compared to the S&P 500, suggesting a potential long-term return equal to the broader market.

**4. Recent Earnings and Outlook**

| Date | EPS | Revenue |
|---|---|---|
| 2024-10-23 | 1.12 | 22.47 B$ |
| 2024-07-25 | 1.95 | 22.45 B$ |
| 2024-05-01 | 1.35 | 21.38 B$ |
| 2024-02-16 | 1.68 | 21.39 B$ |
| 2023-10-27 | 10.32 | 21.35 B$ |

The most recent earnings report for Q3 2024 shows a strong performance with an EPS of 1.12, exceeding analysts' expectations. This positive result could potentially trigger a short-term rebound in the share price. However, it's important to note that overall earnings have been somewhat volatile, with a significant dip in Q4 2023.

**5. Financial Information**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $22.47B | 69.01% |
| 2024-06-30 | $22.45B | 69.40% |
| 2024-03-31 | $21.38B | 69.55% |
| 2023-12-31 | $21.39B | 68.23% |
| 2023-09-30 | $21.35B | 69.06% |

JNJ's revenue has remained relatively stable, demonstrating consistent growth over the last few quarters. Profit margins have been strong, hovering around 70%, indicating efficient operations.

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $70.16B | 3.84% |
| 2024-06-30 | $71.54B | 6.55% |
| 2024-03-31 | $70.02B | 4.65% |
| 2023-12-31 | $68.77B | 5.89% |
| 2023-09-30 | $71.23B | 36.54% |

While equity has been generally stable, ROE has been fluctuating. The spike in Q3 2023 is an outlier, potentially due to specific events. However, overall, JNJ shows strong capital structure and a healthy return on equity.

**6. News and Recent Events**

* You should consult reliable financial news sources like **Shaccknews, FINBOLD** etc. to stay up-to-date on JNJ's latest news and recent events, including earnings announcements, analyst opinions, and market outlook.

**7. Summary**

JNJ has historically been a stable and consistent performer in the pharmaceutical and healthcare sectors. While its recent performance has lagged behind the market, its strong financials and the potential for a rebound from oversold territory provide reasons for optimism. However, investors should consider the company's current undervaluation and the ongoing uncertainty in the market before making any investment decisions.

**Key Points:**

* JNJ's performance has been lagging behind the market, with a significant negative divergence.
* The company's financial position remains strong, with stable revenue and healthy profit margins.
* The recent earnings report showed strong performance, potentially signaling a short-term rebound.
* JNJ is currently in oversold territory, potentially offering an opportunity for a short-term bounce back.
* Long-term investors should continue to monitor JNJ's performance and consider its potential for long-term growth.

**Note:** This analysis is based on the provided information and does not constitute financial advice. Investors should conduct thorough research and consider their individual investment goals and risk tolerance before making any decisions. 
